Navigation Links
Early use of stents better than medical therapy alone for certain patients
Date:8/27/2012

STANFORD, Calif. For patients with stable coronary artery disease who have at least one narrowed blood vessel that compromises flow to the heart, medical therapy alone leads to a significantly higher risk of hospitalization and the urgent need for a coronary stent when compared with therapy that also includes initial placement of artery-opening stents.

Those are the findings of a study to be published online Aug. 28 in the New England Journal of Medicine that was designed to evaluate the benefits of using a diagnostic tool called fractional flow reserve, or FFR, to help determine the best course of treatment for fixing a narrowed artery.

"We believe there is a significant proportion of patients who benefit from stenting early on as opposed to receiving only medical therapy," said William Fearon, MD, associate professor of cardiovascular medicine at the Stanford University School of Medicine and co-principal investigator and senior author of the multi-center international trial called FAME 2. "For this group of patients who have significant ischemia [blood vessel narrowing that compromises flow to the heart muscle] based on assessment with FFR, the need for hospitalization and urgent revascularization is much higher and the pain relief is much less when only medical therapy is prescribed. People feel better and do better with FFR-guided placement of coronary stents up front in this setting."

The study's principal investigator is Bernard De Bruyne, MD, PhD, of Cardiovascular Center Aalst in Belgium.

The trial was halted early, on Jan. 15, because of the high rates of hospitalization and coronary stenting needed in the patients with significant ischemia who received only medical therapy. Some of those patients had suffered subsequent chest pain and heart attacks requiring urgent revascularization, which entails repairing damaged blood vessels with emergency stenting or heart bypass surgery.

Narrowing of the arteries caused by buildup of atherosclerotic plaque is common. About 40 percent of Americans over the age of 60 have one or more narrowings in the coronary arteries but no symptoms or stable symptoms, a condition known as stable coronary artery disease. Many can be treated with medical therapy alone, which may include aspirin or statins.

The idea for this trial grew out of the landmark COURAGE trial, presented in 2007, which found that stenting didn't provide any significant benefits over medical therapy for people with stable coronary artery disease. That trial relied solely on X-rays from coronary angiograms and noninvasive stress tests to determine which patients needed stenting.

The FAME 1 trial, which Fearon also helped coordinate, published in the NEJM in 2009 showed that doctors should go one step beyond the traditional method of relying solely on angiograms and use the additional method of measuring FFR to determine which arteries should or should not be stented for patients with coronary artery disease. Its findings demonstrated that FFR-guided stenting decreased a patient's chance of dying, having a heart attack or needing a repeat coronary revascularization, and reduced the number of stents necessary, thereby saving money.

The FAME 2 trial also used FFR, which involves inserting a coronary pressure guide wire into the artery to measure blood flow. In this study, it helped doctors pinpoint which patients would benefit from early stenting, as it identifies vessels with blood flow reduced to a dangerous level. As the study documented, these patients need stenting to prevent future adverse events.

"It's hard to know which patients are ischemic and which are not," said Morton Kern, MD, professor of cardiology at the University of California-Irvine. Kern was not directly involved with research on the study, but was a consultant on safety. "FFR is a very simple marker to help identify ischemia."

The cost is low, an additional $700 compared to the average cost of a stent, which is roughly $2,000. And the FFR technology is available to most physicians, he said.

The study included 888 patients with at least one stenosis one significantly narrowed artery causing ischemia that was identified with FFR. An artery was considered seriously narrowed if the blood pressure was 80 percent or less past the narrowing than the pressure in front of the narrowing. Patients were enrolled in 28 centers in Europe, the United States and Canada. Fifty patients were enrolled at Stanford University Medical Center and the Veterans Affairs Palo Alto Health Care System in the portion of the trial led by Fearon.

Trial participants were randomly assigned to either medical therapy alone or medical therapy combined with stenting.

Patient enrollment began May 15, 2010. By Jan. 15 of this year, 75 patients in the trial had experienced at least one "cardiac event," such as the need for hospitalization and an urgent stent or a heart attack. The rate of these events was 4.3 percent for patients randomized to stents plus medical therapy compared with 12.7 percent in patients assigned to medical therapy.


'/>"/>

Contact: Tracie White
traciew@stanford.edu
650-723-7628
Stanford University Medical Center
Source:Eurekalert

Related medicine news :

1. New Stool Test Might Aid in Early Detection of Colon Cancer
2. An Early Start for Your Child with Autism
3. Early Study Finds Some Promise for Lung Cancer Vaccine
4. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
5. JCI early table of contents for April 9, 2012
6. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. First contact: Early intervention key in diagnosis and treatment of serious mental illness
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following ... Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida ... went to school and at 19 years of age, he joined the Navy and got ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Next week after ... be repealed by Congressional political games that circumvent health needs of over 30 million. ... capture the human anxieties and needs government public servants were suppose to prioritize. Interviews ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
(Date:1/19/2017)... Jan. 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced ... institution supporting research in Germany , ... treatments at the University Clinic Heidelberg as part of ... MRIdian Linac program will be headed by Medical Director ... radiation oncology at the German Cancer Research Center (DKFZ), ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
Breaking Medicine Technology: